Cargando…

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients

Neutropenia and febrile neutropenia (FN) are frequent and potentially fatal toxicities of myelosuppressive anticancer treatments. The introduction of granulocyte colony-stimulating factors (G-CSFs) in clinical practice has remarkably reduced the duration and severity of neutropenia, as well as the i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guariglia, Roberto, Martorelli, Maria Carmen, Lerose, Rosa, Telesca, Donatella, Milella, Maria Rita, Musto, Pellegrino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730998/ https://www.ncbi.nlm.nih.gov/pubmed/26858523 http://dx.doi.org/10.2147/BTT.S58597

Ejemplares similares

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
por: Hoggatt, Jonathan, et al.
Publicado: (2015)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
Publicado: (2015)

Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events
por: Bond, T Christopher, et al.
Publicado: (2017)

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
por: Akpo, Esse I. H., et al.
Publicado: (2017)

Review on lipegfilgrastim
por: Gasparic, Maja, et al.
Publicado: (2015)

Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy
por: Zou, Linglong, et al.
Publicado: (2016)

An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer
por: Rashed, Ahmed, et al.
Publicado: (2023)

Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF
por: Lehmacher, W., et al.
Publicado: (2016)

A pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma
por: Belogurova, Margarita B., et al.
Publicado: (2016)

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
por: Hashiguchi, Yasunori, et al.
Publicado: (2015)

Management of chemotherapy-associated febrile neutropenia
por: Cameron, D
Publicado: (2009)

Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy
por: do Nascimento, Talita Garcia, et al.
Publicado: (2014)

Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting
por: Merseburger, Axel S., et al.
Publicado: (2021)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study
por: Link, Hartmut, et al.
Publicado: (2020)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
por: Bondarenko, Igor, et al.
Publicado: (2013)

Properdin Levels in Individuals with Chemotherapy-Induced Neutropenia
por: Tsyrkunou, Artsiom, et al.
Publicado: (2016)

Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
por: Boccia, Ralph, et al.
Publicado: (2022)

Prescribing patterns from medical chart abstraction of patients administered lipegfilgrastim: a pilot study in Europe
por: Kaplan, Sigal, et al.
Publicado: (2019)

An Urologic Face of Chronic Lymphocytic Leukemia: Sequential Prostatic and Penis Localization
por: D’Arena, Giovanni, et al.
Publicado: (2013)

Chemotherapy induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria
por: Salako, Omolola, et al.
Publicado: (2021)

Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells
por: Russo, Massimo, et al.
Publicado: (2023)

Nurses’ knowledge of chemotherapy-induced neutropenia and its management: a cross-sectional survey
por: Al Qadire, Mohammad, et al.
Publicado: (2022)

New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim
por: Ghidini, Michele, et al.
Publicado: (2016)

Towards Quantitative Systems Pharmacology Models of Chemotherapy‐Induced Neutropenia
por: Craig, M
Publicado: (2017)

Chemotherapy-Induced Neutropenia in Pediatric Leukemia: Persian Medicine Perspective
por: Daneshfard, Babak, et al.
Publicado: (2019)

Serum protein and electrolyte imbalances are associated with chemotherapy induced neutropenia
por: Abbasi, Benazir, et al.
Publicado: (2022)

Bloodstream infection in pediatric patients with febrile neutropenia induced by chemotherapy
por: Lima, Mariana Antunes Faria, et al.
Publicado: (2023)

Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer
por: Ma, Rui-Min, et al.
Publicado: (2016)

Pasteurella multocida Bacteremia in a Patient With Ovarian Cancer and Chemotherapy-induced Neutropenia
por: Casey, A. Catherine, et al.
Publicado: (1995)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Microbial Translocation Contribute to Febrile Episodes in Adults with Chemotherapy-Induced Neutropenia
por: Wong, Michelle, et al.
Publicado: (2013)

Macrophage Colony‐stimulating Factor Prevents Febrile Neutropenia Induced by Chemotherapy
por: Hidaka, Takao, et al.
Publicado: (2001)

Pulmonary Infectious Complications in Children with Hematologic Malignancies and Chemotherapy-Induced Neutropenia
por: Voulgaridou, Aikaterini, et al.
Publicado: (2020)

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012)

Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities
por: Fortner, Barry V, et al.
Publicado: (2004)

Resolution of Disseminated Intravascular Coagulation in a Patient with COVID-19 and Associated Sepsis—Induced Neutropenia
por: Di Micco, Pierpaolo, et al.
Publicado: (2021)

Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy
por: Bachlitzanaki, Maria, et al.
Publicado: (2023)

A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy
por: Buchner, Anton, et al.
Publicado: (2014)

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy
por: Volovat, Constantin, et al.
Publicado: (2015)

Appraising of the Clinical Practice Guidelines Quality in the Non-Pharmacological Management of Chemotherapy-Induced Febrile Neutropenia; A Review
por: Salarvand, Shahin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_907lv8ifm39onfq5ling6ofr5e